Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Iveric Bio

Multiple Stargardt Contenders Progress In Japan Despite Small Market

With no approved therapies globally for Stargardt's, competition in the indication is increasing in Japan, where Kubota Vision is seeking for conditional approval for emixustat, while Belite Bio’s contender tinlarebant has received Sakigake designation as a local Phase III program continues.

Japan Research & Development

Astellas’s US Commercial Head Petroutsas On New Launches

The Japanese pharma’s new US commercial head Michael Petroutsas talked to Scrip about the launches of Veozah and Izervay.

Launches Leadership

EY: Buyers Need To Fill Revenue Gaps But M&A Targets May Be Scarce

In its Beyond Borders 2024 report, coinciding with the start of the BIO meeting, EY analysts see declining revenues for big pharma, which could be addressed by M&A, if the right takeouts exist.


Astellas Rejigs R&D Focus Areas As It Withdraws From Mitochondria R&D

As Astellas pivots through several candidates in an attempt to create its next blockbuster, a decision to terminate its only prospect in the core mitochondrial R&D area leaves very few other competitors in the market.

Research & Development Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Inception 4, Inc.
    • Ophthotech Corporation (OPHT)